GE Healthcare Enhances Workflow in Echo Lab, OR and Cath Lab with Vivid E9 Cardiovascular Ultrasound, Now Including 4D TEE Transducer

WAUWATOSA, Wis.--(BUSINESS WIRE)--GE Healthcare, a unit of General Electric Company (NYSE: GE), today announced the FDA clearance and availability of the latest version of its Vivid E9™ cardiovascular ultrasound system. The Vivid E9 Breakthrough 2012 (BT12) includes a 4D transducer for transesophageal echocardiography (TEE), and also provides innovative tools designed to help improve workflow efficiency through simplified image acquisition, intuitive navigation and advanced, yet easy to use quantification.

Back to news